Developing life more humann
We’re focused on creating the cutting-edge therapies and technologies that can change life for the better.
Our pipeline reflects how we, as well as our partners, are applying MannKind technology to develop and advance new products to not only help people take control of their health, but truly thrive.
Cardiometabolic
Orphan Lung
| Product | Targeted Indications | Pre-IND | Phase 1 | Phase 2 | Phase 3 | Approval |
|---|---|---|---|---|---|---|
Afrezza® (insulin human) Inhalation
Powder
|
|
|
||||
|
V-Go® All-in-One Insulin Delivery Patch
|
|
|
||||
|
Furoscix® / Furoscix ReadyFlow™ (furosemide injection)
|
|
|
||||
|
Bumetanide DPI (MNKD – 701) |
|
|
||||
|
Tyvaso DPI® (treprostinil) Inhalation Powder (marketed by United Therapeutics) 
|
|
|
||||
|
Nintedanib DPI (MNKD – 201) |
|
|
||||
|
Ralinepag DPI (MNKD-1501; collaboration with United Therapeutics) |
|
|
|
T1DMType 1 Diabetes Mellitus PAHPulmonary Arterial Hypertension
|
T2DMType 2 Diabetes Mellitus PH-ILDPulmonary Hypertension Associated with Interstitial Lung Disease
|
HFHeart Failure IPFIdiopathic Pulmonary Fibrosis
|
CKDChronic Kidney Disease PPFProgressive Pulmonary Fibrosis
|
